A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

Elens, Laure;Bouamar, Rachida;Hesselink, Dennis A;Haufroid, Vincent;van Schaik, Ron H N;et.al.
(2011) Clinical Chemistry : international journal of molecular diagnostics and laboratory medicine — Vol. 57, n° 11, p. 1574-1583 (2011)

Files

No attached file found for this publication.

Details

Authors
Show more
Abstract
Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity. Tac pharmacokinetics varies between individuals and thus complicates its use in preventing rejection after kidney transplantation. This variability might be caused by genetic polymorphisms in metabolizing enzymes.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Elens, L., Bouamar, R., Hesselink, D. A., Haufroid, V., van der Heiden, I. P., van Gelder, T., & van Schaik, R. H. N. (2011). A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clinical Chemistry : international journal of molecular diagnostics and laboratory medicine, 57(11), 1574-1583. https://doi.org/10.1373/clinchem.2011.165613 (Original work published 2011)